


Current Biology

Ligation of newly replicated DNA controls the timing of DNA mismatch repair

Graphical Abstract



Authors

Gloria X. Reyes, Anna Kolodziejczak, Lovely Jael Paul Solomon Devakumar, Takashi Kubota, Richard D. Kolodner, Christopher D. Putnam, Hans Hombauer

Correspondence

h.hombauer@dkfz.de

In Brief

The correction of DNA replication errors by the mismatch repair (MMR) machinery requires the discrimination between parental and daughter DNA strands. Reyes et al. provide evidence that DNA replication-associated nicks are used as MMR strand discrimination signals and that DNA ligase I (Cdc9) activity dictates a window of time for MMR.

Highlights

- Cdc9 overexpression causes increased mutation rates and accumulation of Pms1 foci
- DNA replication-associated nicks are required for MMR strand discrimination
- Cdc9 activity dictates a temporal window for MMR



Report

Ligation of newly replicated DNA controls the timing of DNA mismatch repair

Gloria X. Reyes,^{1,10} Anna Kolodziejczak,^{1,2,10} Lovely Jael Paul Solomon Devakumar,³ Takashi Kubota,³ Richard D. Kolodner,^{4,5,6,7} Christopher D. Putnam,^{4,8} and Hans Hombauer^{1,9,11,*}

¹DNA Repair Mechanisms and Cancer, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany

²Faculty of Bioscience, Heidelberg University, Heidelberg 69120, Germany

³Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Foresterhill, Aberdeen, Scotland AB25 2ZD, UK

⁴Ludwig Institute for Cancer Research, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0669, USA

⁵Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0669, USA

⁶Moore's Cancer Center at UC San Diego Health, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0669, USA

⁷Institute of Genomic Medicine, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0669, USA

⁸Department of Medicine, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0669, USA

⁹Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), Heidelberg 69120, Germany

¹⁰These authors contributed equally

¹¹Lead contact

*Correspondence: h.hombauer@dkfz.de
<https://doi.org/10.1016/j.cub.2020.12.018>

SUMMARY

Mismatch repair (MMR) safeguards genome stability through recognition and excision of DNA replication errors.^{1–4} How eukaryotic MMR targets the newly replicated strand *in vivo* has not been established. MMR reactions reconstituted *in vitro* are directed to the strand containing a preexisting nick or gap,^{5–8} suggesting that strand discontinuities could act as discrimination signals. Another candidate is the proliferating cell nuclear antigen (PCNA) that is loaded at replication forks and is required for the activation of Mlh1-Pms1 endonuclease.^{7–9} Here, we discovered that overexpression of DNA ligase I (Cdc9) in *Saccharomyces cerevisiae* causes elevated mutation rates and increased chromatin-bound PCNA levels and accumulation of Pms1 foci that are MMR intermediates, suggesting that premature ligation of replication-associated nicks interferes with MMR. We showed that yeast Pms1 expression is mainly restricted to S phase, in agreement with the temporal coupling between MMR and DNA replication.¹⁰ Restricting Pms1 expression to the G2/M phase caused a mutator phenotype that was exacerbated in the absence of the exonuclease Exo1. This mutator phenotype was largely suppressed by increasing the lifetime of replication-associated DNA nicks, either by reducing or delaying Cdc9 ligase activity *in vivo*. Therefore, Cdc9 dictates a window of time for MMR determined by transient DNA nicks that direct the Mlh1-Pms1 in a strand-specific manner. Because DNA nicks occur on both newly synthesized leading and lagging strands,¹¹ these results establish a general mechanism for targeting MMR to the newly synthesized DNA, thus preventing the accumulation of mutations that underlie the development of human cancer.

RESULTS AND DISCUSSION

DNA mismatch repair (MMR) utilizes an excision-resynthesis mechanism to correct mispaired bases that occur in DNA due to errors during DNA synthesis.^{1–4} To repair these errors, MMR must target only the newly synthesized daughter strand; however, it remains unclear how this machinery discriminates between the parental strand and the daughter strand in eukaryotic living cells. It is known that eukaryotic MMR is temporally coupled to DNA replication, as newly replicated DNA in *S. cerevisiae* is proficient for MMR for no longer than 10 min during S phase.¹⁰ This result suggests that the MMR strand-discrimination signal in eukaryotes involves some aspect of the DNA replication machinery and/or an S-phase-associated property of the daughter strand itself.

Several studies in eukaryotes have investigated transient features of the newly replicated DNA as candidate strand-discrimination signals. Single-strand discontinuities (nicks) present between Okazaki fragments or those generated upon removal of misincorporated ribonucleotides have been proposed to serve as strand-discrimination signals.^{12,13} However, the inactivation of the ribonucleotide excision repair (RER) pathway causes far lower mutation rates than complete loss of MMR and results in an unusual spectrum of mutations whose formation depends on the activity of topoisomerase I.¹⁴ In contrast, mutations affecting MMR strand-discrimination components in *Escherichia coli*, including the Dam methylase or the MutH endonuclease, result in complete loss of MMR function.¹⁵ Another candidate is Proliferating Cell Nuclear Antigen (PCNA), which is loaded asymmetrically at the replication fork,¹⁶ interacts with



Msh2-Msh6,¹⁷ and stimulates the latent endonuclease activity of Mlh1-Pms1 (called MLH1-PMS2 in human).^{7–9,18,19} PCNA has been proposed to act as a strand-discrimination signal even in the absence of daughter strand discontinuities.²⁰ However, this mechanism is not consistent with the very modest increase in mutation rate caused by loss of the Msh6-PCNA interaction that would be required to target Msh2-Msh6 to newly replicated DNA or retain PCNA at the mispair site.¹⁷ Furthermore, the ability of new PCNA trimers to be loaded at nicks in DNA raises the question of whether replication-associated PCNA or replication-associated nicks are ultimately the strand discrimination signal.

If DNA nicks are MMR strand-discrimination signals *in vivo*, we reasoned that overexpression of the replicative DNA ligase Cdc9 in *S. cerevisiae* should reduce nick lifetime in newly replicated DNA and potentially cause a mutator phenotype. To increase the expression of Cdc9, we constructed high-copy-number vectors expressing wild-type (WT) *CDC9*, two *CDC9* ligase-defective mutants (*cdc9-K419A* and *cdc9-K598A*),^{21,22} and a Cdc9 variant that does not interact with PCNA *in vitro* (*cdc9-FFAA*).²³ Next, we examined whether these plasmids could support the growth of a yeast strain in which the endogenous Cdc9 protein was depleted using the auxin-inducible degron (AID) system.²⁴ For this, we generated a yeast strain with a chromosomally encoded version of *CDC9* fused to the AID-tag (*CDC9-AID*), which, in the presence of the plant hormone auxin and the auxin-receptor Afb2, triggers the ubiquitin-mediated proteasomal degradation of the protein fused to the AID-tag. In agreement with previous results,²⁵ WT-*CDC9* and the *cdc9-FFAA* mutant promoted survival of the *CDC9-AID* strain on auxin-containing medium, whereas the ligase-defective mutants did not (Figure S1A), despite similar levels of expression (Figure S1B). WT Cdc9 overexpression driven by this high-copy-number plasmid caused a modest increase in mutation rates in a WT strain and a strong mutator phenotype in an *exo1Δ* strain (Figure 1A; Table S1), which lacks the Exo1-dependent MMR pathway.^{26,27} This increase in the mutation rates was also observed, to a lesser extent, with the *cdc9-FFAA* allele but was not seen with ligase-defective mutants, indicating that this mutagenic effect requires the overexpression of ligase-proficient Cdc9 and is promoted by an intact PCNA interaction motif. These requirements differ from the trinucleotide repeat (TNR) instability phenotype caused by Cdc9 overexpression, which depends on PCNA recruitment but not on ligase activity and was attributed to a competition between Cdc9 and the flap endonuclease Rad27 for PCNA binding.²²

Mispair recognition by Msh2-Msh6 or Msh2-Msh3 promotes recruitment of the Mlh1-Pms1 endonuclease. Recruitment can be observed as discrete foci in yeast strains expressing a Pms1-4GFP fusion; these Pms1 foci are MMR intermediates that accumulate when downstream MMR functions are compromised (due to mutations affecting Exo1 or preventing the activation of the Mlh1-Pms1 endonuclease) or due to increased levels of mispaired bases.^{19,28,29} Overexpression of WT-*CDC9* or *cdc9-FFAA* in an *exo1Δ* strain caused an increase in the percentage of Pms1 foci-containing cells with ≥ 2 foci per cell (Figures 1B and 1C). In contrast, overexpression of ligase-defective *cdc9* variants modestly reduced Pms1 foci levels. These results suggest that overexpression of functional Cdc9 either slows

downstream steps in MMR or inhibits MMR at a step prior to Mlh1-Pms1 turnover.

In agreement with the Cdc9-overexpression plasmid-based results, we found that strains in which we replaced the endogenous *CDC9* promoter with the strong constitutive promoter *pGPD* (*CDC9-OE*) (causing a ~ 50 -fold increase in Cdc9 levels; Figure S1C) showed a modest mutator phenotype that was greatly exacerbated by mutations that prevent Exo1-dependent MMR (an *EXO1* deletion or an *exo1-FFAA-Δ571-702* mutant allele, which cannot be recruited by Msh2 or Mlh1 to MMR sites³⁰) (Figure 2A; Table S2). To determine whether MMR defects induced by *CDC9-OE* were only seen in the presence of defects in Exo1-dependent MMR, we combined the *CDC9-OE* allele with mutations that disrupt the Exo1-independent MMR pathway: *pol30-K217E*, which prevents PCNA-dependent activation of the Mlh1-Pms1 endonuclease¹⁹ and *pms1-A99V* (previously called *pms1-A130V*), which affects a residue in the Pms1 ATPase domain and reduces endonuclease activation.²⁶ We found that *CDC9-OE* caused a synergistic increase in mutation rates in combination with both the *pol30-K217E* and *pms1-A99V* mutations, indicating that Cdc9 overexpression affects both Exo1-dependent and Exo1-independent MMR pathways (Figure 2A). Consistent with this, the *CDC9-OE exo1Δ pol30-K217E* triple mutant had mutation rates that were significantly higher than those of the *exo1Δ pol30-K217E*, *CDC9-OE exo1Δ* and *CDC9-OE pol30-K217E* double mutants. Even though the *CDC9-OE* allele in combination with an *msh2Δ* mutation did not cause a synergistic increase in frameshift mutation rates (Figure 2A), the *CDC9-OE exo1Δ pol30-K217E* triple mutant showed mutation rates that were modestly higher than that of the MMR-deficient *msh2Δ* strain (Figure 2A; Table S2). This result raises the possibility that some interaction between Cdc9 overexpression, the absence of Exo1, and disruption of the positively charged surface at the PCNA-DNA interaction surface caused by the *pol30-K217E* mutation leads to an increased accumulation of mispairs that does not occur when Cdc9 is overexpressed in the absence of MMR.

We hypothesized that the impaired MMR function caused by *CDC9-OE* could be the result of the premature ligation of DNA replication-associated nicks. Leading-strand nicks have been suggested to be due to the processing of misincorporated ribonucleotides, as Pol ϵ , the leading-strand DNA polymerase, incorporates ribonucleotides four times more frequently than Pol δ , the lagging-strand DNA polymerase.³¹ If ribonucleotide excision plays an important role in MMR strand discrimination, then combining the *CDC9-OE* allele with a deletion of the *RNH201* gene, which encodes the catalytic subunit of RNase H2, should cause increased mutation rates. In contrast, we found that mutation rates in the double-mutant strain *CDC9-OE rnh201Δ* were similar to that of the *CDC9-OE* strain; and the *CDC9-OE exo1Δ rnh201Δ* triple mutant was no more MMR defective than the *CDC9-OE exo1Δ* strain (Figure 2B; Table S2). These results suggest that RER-associated strand discontinuities are not a major source of MMR strand-discrimination signals.

To further characterize the mutator phenotype associated with Cdc9 overexpression, we analyzed *CAN1* mutational spectra. The *CAN1* mutation spectrum of the *CDC9-OE* single mutant showed a similar frequency of base substitutions, a reduced frequency of frameshift mutations, and twice as many complex




Figure 1. Increased Cdc9 activity results in elevated mutation rates and accumulation of Pms1 foci

(A) Mutation rate analysis using the *lys2-10A* frameshift reversion assay in WT or *exo1Δ* strains carrying plasmids (2 μ) bearing WT-*CDC9*, the PCNA interaction-deficient *cdc9-FFAA* mutant, the ligase-defective mutants *cdc9-K419A* and *cdc9-K598A*, or an empty vector (ev). Bars correspond to the median rate, with error bars corresponding to the 95% confidence interval. Numbers on top of the bars indicate fold increase in mutation rate relative to the WT strain. See also Figure S1 and Table S1.

(B) Percentage of cells containing Pms1-4GFP foci in *exo1Δ* strains transformed with plasmids shown in (A). Bars represent the average of the percentage of nuclei containing foci; error bars represent standard error of the mean (SEM).

(C) Representative fluorescent microscopy live-cell images of cells containing Pms1 foci used for quantification shown in (B). Brightfield images are shown on top. Scale bar represents 5 μ m. p values indicated in (A) and (B) were calculated with the Mann-Whitney rank-sum test using SigmaPlot. *p \leq 0.05; **p \leq 0.01; ***p \leq 0.001; n.s., not significant.

mutations as the WT strain (Table S3). These complex mutations consisted of duplications or deletions (ranging from 15 to 72 bp) flanked by direct repeats (Table S4) that strongly resemble the mutations that arise in a *rad27Δ* mutant.³² This observation, together with the TNR-instability phenotype reported for the *CDC9-OE* strain,²² supports the idea that *CDC9-OE* interferes with Rad27-dependent Okazaki fragment maturation, resulting in large deletions and duplications that are not restricted to DNA sequences containing TNRs. Consistent with this hypothesis, combining the *CDC9-OE* allele with an *msh2Δ* mutation did not cause a synergistic increase in mutation rates using MMR-specific mutation rate assays (*lys2-10A* and *hom3-10* frameshift reversion assays), but it did cause elevated rates in the *CAN1* inactivation assay, which detects a broader spectrum of

mutations than just those caused by MMR defects (Figure 2A; Table S2). In contrast, the *CAN1* mutational spectrum of the *exo1-FFAA-Δ571-702* single mutant was indistinguishable from that of the WT strain (Table S3). Remarkably, the mutation spectrum of the *CDC9-OE exo1-FFAA-Δ571-702* double mutant was dominated by single-base frameshift mutations, primarily in the three longest mononucleotide runs within the *CAN1* gene (six consecutive A or T bases). This spectrum is very similar to that of the *msh2Δ* strain³³ and is characteristic of MMR-deficient strains. The difference between the *CAN1* mutational spectra of the *CDC9-OE* single-mutant and the *CDC9-OE exo1-FFAA-Δ571-702* double-mutant strains suggests that the elevated *CAN1* mutation rate in the double mutant is caused by an increased MMR defect and not an increased defect in




Figure 2. Cdc9 overexpression interferes with both Exo1-dependent and Exo1-independent MMR pathways

(A and B) Mutation rate analysis using the *lys2-10A* frameshift reversion reporter in the indicated yeast genetic backgrounds. Bars correspond to the median rate, with error bars representing the 95% confidence interval. Numbers on top of the bars indicate fold increase in mutation rate relative to WT. p values were calculated with the Mann-Whitney rank-sum test using SigmaPlot. ***p ≤ 0.001; n.s., not significant. See also Table S2 for additional mutation rate analysis using two alternative mutational reporters.

Rad27-dependent Okazaki fragment maturation that would result in the accumulation of large insertion and deletion mutations.

We considered the possibility that the MMR defects in *Cdc9*-overexpressing strains could be caused by reduced levels of PCNA impairing the activation of the Mlh1-Pms1 endonuclease, as PCNA unloading by the Replication factor C-like complex (RLC)-Elg1 depends on Okazaki fragment ligation.²⁵ We therefore analyzed the effect of a *CDC9-OE* allele on chromatin-bound PCNA levels (Figures 3A and S1D). As a control, we included strains carrying the *pol30-C81R* allele or an *elg1Δ* mutation, which cause reduced or increased levels of chromatin-bound PCNA, respectively.^{34,35} We found that *CDC9-OE* caused

an increased level of chromatin-bound PCNA (2-fold higher than WT), suggesting that the mutator phenotype and the accumulation of Pms1 foci in *CDC9-OE* strains are not a consequence of reduced chromatin-bound PCNA. This increased chromatin-bound PCNA is consistent with the results of previous experiments *in vitro* showing that excesses of PCNA-interacting proteins (e.g., Polδ, FEN1, and DNA ligase I) prevent the RLC-Elg1-dependent unloading of PCNA from DNA, most likely by occluding access to the RLC-Elg1-unloader complex.³⁶ Deletion of *ELG1* resulted in the accumulation of PCNA and SUMOylated PCNA (indicated by high-molecular-weight bands recognized by the PCNA-specific antibody) on chromatin (Figure S1D), in accordance with a previous report.³⁵ Similar accumulation of chromatin-bound PCNA was observed in the *CDC9-OE elg1Δ* double-mutant strain (Figure 3A). In contrast, chromatin-bound PCNA levels were reduced by overexpression of *ELG1* (*ELG1-OE*) in both WT and *CDC9-OE* strains. Furthermore, *ELG1-OE* caused a synergistic increase in mutation rate in the *CDC9-OE exo1Δ* double mutant, resulting in mutation rates comparable to that of an *msh2Δ* single mutant, but only caused a small effect when combined with an *exo1Δ* mutation (Figure 3B; Table S2). In addition, *ELG1-OE* resulted in increased levels of Pms1 foci by itself and in combination with either *exo1Δ* or *CDC9-OE* alleles (Figure 3C). Together, these results suggest that *ELG1-OE*-driven loss of chromatin-bound PCNA interferes with MMR by a different mechanism than *CDC9-OE*. Interestingly, mutations resulting in a reduction in chromatin-bound PCNA do not strictly correlate with increased mutation rates (e.g., the *ELG1-OE* allele, which causes reduced chromatin-bound PCNA levels, causes a mild mutator phenotype, even in combination with an *exo1Δ* mutation) (Figures 3A and 3B; Table S2). Furthermore, it suggests that the subpopulation of PCNA localized at mismatch sites—which activates the Mlh1-Pms1 endonuclease—is present at levels that do not directly correlate with the total amount of chromatin-bound PCNA. Deletion of *ELG1* (*elg1Δ*) causes a mild mutator phenotype, even in combination with an *exo1Δ* mutation or with the *CDC9-OE* allele, and suppresses the mutator phenotype of a *CDC9-OE exo1Δ* strain in the *lys2-10A* assay (Figure 3D; Table S2). This observation suggests that increased chromatin-bound PCNA levels can partially compensate for the effects caused by *CDC9-OE* and/or *EXO1* deletion.

We have previously restricted the availability of the Msh2-Msh6 mismatch recognition complex to the G2/M phase in living cells by fusing the *MSH6* gene to the “G2/M-tag” (derived from the cyclin *CLB2* promoter and the *Cib2* destruction box; residues 1–181).¹⁰ Yeast strains expressing the G2/M-Msh6 fusion protein (in an *msh3Δ* background to eliminate any repair mediated by the partially redundant Msh2-Msh3 heterodimer) were MMR deficient at loci replicated in mid-S phase but were proficient for MMR at loci replicated in late S phase or at mid-S-phase loci moved to a late-S-phase replication site.¹⁰ These previous findings together with the observation that *CDC9-OE* interferes with MMR suggest that the lifetime of replication-associated nicks control the temporal window for MMR. To test this, we fused the G2/M tag to *CDC9* to generate a strain in which *CDC9* expression was restricted to G2/M so that replication-associated nicks persist throughout S phase (Figure 4A). Consistent with a recent report,³⁷ strains carrying the G2/M-*CDC9* allele were viable and had increased levels of unligated Okazaki




Figure 3. Increased mutagenesis caused by *Cdc9* overexpression is not due to the premature unloading of PCNA from DNA


(A) PCNA levels in whole cell extracts (WCE) and chromatin fractions. Histone H3 was the loading control. See also Figure S1D.

(B–D) In (B) and (D): mutation rate analysis using the *lys2-10A* frameshift reversion reporter in the indicated yeast genetic backgrounds. Bars correspond to the median rate, with error bars indicating the 95% confidence interval. Numbers on top of the bars indicate fold increase in mutation rate relative to WT. See also Table S2 for additional mutation rate analysis and Tables S3 and S4 for *CAN1* mutation spectra analysis. (C) Correlation between Pms1-foci abundance and frameshift mutator phenotype (*hom3-10* assay). Quantification of Pms1-4GFP foci in boxplot with whiskers; dots represent outliers; black and red lines inside the boxplot represent the median and the average, respectively. Statistical analysis indicated in (C) was performed relative to WT. p values shown in (B)–(D) were calculated with the Mann-Whitney rank-sum test using SigmaPlot. **p ≤ 0.01; ***p ≤ 0.001; n.s., not significant.

fragments relative to WT cells in S phase (Figure S2) but not in G2/M phase when G2/M-*Cdc9* is expressed (Figure 4A) or in G1 phase. Moreover, strains expressing G2/M-*Cdc9* exhibited DNA-damage checkpoint activation and an accumulation of cells in S phase (Figures S3A–S3C). In contrast, a strain carrying the *cdc9-FFAA* mutant allele, which is expected to have reduced ligase efficiency but normal expression timing, did not show DNA-damage checkpoint activation or an accumulation of S-phase cells (Figures S3A–S3C) and had less pronounced and slightly larger Okazaki fragments than G2/M-*CDC9* when cells were arrested in S or G2/M phase (Figure S2).

The G2/M-*CDC9* allele did not suppress the MMR defect of the G2/M-*MSH6* *msh3Δ* mutant strain measured at three mid-

S phase-replicated loci (Table S5), which is consistent with the idea that mismatch recognition must occur during DNA replication.¹⁰ We therefore constructed the G2/M-*PMS1* allele to restrict MMR steps after mismatch recognition to the G2/M phase of the cell cycle (Figure 4A). The G2/M-*PMS1* allele caused a mutator phenotype that was exacerbated by an *exo1Δ* mutation at three mid-S phase-replicated loci (replication time, 32–39 min after release from α -factor arrest)³⁸ (Figure 4B; Table S5). In contrast, the G2/M-*PMS1* allele was 4 times more proficient at suppressing mutations when the *lys2-10A* reporter was moved to a late-replicated region (*lys2-10A_{LATE}*),¹⁰ which is replicated 49 min after release from α -factor arrest³⁸ (Figure 4B) and coincides with the time when G2/M-Pms1 reaches the peak level in



expression (Figure 4A). If nicks were the daughter-strand discrimination signal, the *G2/M-PMS1* mutator phenotype could be due to the temporal uncoupling of this signal and the repair machinery. Thus, we reasoned that mutations that cause the signal to persist should suppress the *G2/M-PMS1* mutator phenotype. Remarkably, when the *G2/M-PMS1* or the *G2/M-PMS1 exo1Δ* alleles were combined with the *G2/M-CDC9* or the *cdc9-FFAA* allele, the mutator phenotype was largely suppressed (Figure 4B; Table S5), with *G2/M-CDC9* resulting in stronger suppression. This observation is in agreement with the more pronounced and slightly shorter Okazaki fragments (indicative of a stronger Cdc9 ligase defect) in the *G2/M-CDC9* strain arrested in S phase, compared to the *cdc9-FFAA* strain arrested in either S or G2/M phase (Figure S2B). It should be noted that the peak of G2/M-Cdc9 protein expression occurs 20 min after the peak of G2/M-Pms1 protein expression, which could explain why G2/M-Cdc9 protein expression does not inhibit MMR in the *G2/M-PMS1* strain. Furthermore, deletion of *ELG1*,

Figure 4. Cdc9 activity dictates a window of time for MMR strand discrimination

(A) Top: Pms1 and Cdc9 protein expression levels throughout the cell cycle under endogenous regulation (*PMS1-6HA* and *CDC9-9MYC*) or under control of the G2/M-tag (*G2/M-PMS1-6HA* and *G2/M-CDC9-9MYC*). Bottom: logarithmically growing cells (log), α -factor-arrested cells (α -F), or cells arrested and released from α -F arrest for the indicated time were analyzed by western blotting and DNA content analysis. Sic1, Clb2, and tubulin serve as G1-, G2/M-phase, and loading controls, respectively. See also Figures S2 and S3.

(B) Mutation rate analysis using the *lys2-10A* frameshift reversion assay in the indicated strains. Bars correspond to the median rate, with error bars representing the 95% confidence interval. Numbers on top of the bars indicate fold increase in mutation rate relative to the WT. p values were calculated with the Mann-Whitney rank-sum test using SigmaPlot. ***p \leq 0.001; n.s., not significant. See also Table S5 for additional mutation rate analysis using two alternative mutational reporters.

which increases the amount of chromatin-associated PCNA (Figure S1D),³⁵ resulted in a modest rescue of the mutator phenotype of *G2/M-PMS1 exo1Δ* (Figure 4B; Table S5). The suppression of the *G2/M-PMS1 exo1Δ* mutator phenotype by the previous mutations is unlikely to be related to changes in cell-cycle progression or activation of the DNA damage response, as log-phase cultures of the *G2/M-PMS1 exo1Δ elg1Δ* and the *G2/M-PMS1 G2/M-CDC9 exo1Δ* triple mutants had relatively normal DNA content profiles (Figure S3C). These results, together with the observation that the *cdc9-FFAA* allele (which affects neither cell-cycle progression nor

DNA damage response) also suppressed the *G2/M-PMS1 exo1Δ* strain mutator phenotype, indicate that the suppressive effects of the *G2/M-CDC9* and *cdc9-FFAA* alleles are a consequence of the inefficient ligation of DNA replication-associated nicks. Thus, by delaying the ligation of DNA replication-associated nicks, it is possible to retain MMR proficiency up to G2/M phase for loci replicated in mid-S phase.

In conclusion, our findings indicate that MMR is sensitive to the timing of DNA ligation and the lifetime of replication-associated nicks in DNA. Increased ligase activity causes a mutator phenotype, whereas reduced or delayed ligase activity prolongs the temporal window in which loci can undergo MMR. Importantly, these effects on MMR did not correlate with the bulk levels of chromatin-bound PCNA and were unaffected by loss of ribonucleotide excision. Thus, these results suggest that replication-associated nicks are the *in vivo* strand-discrimination signals in eukaryotes, consistent with the requirement of pre-existing nicks in reconstituted MMR reactions *in vitro*.^{5–8}

If nicks act to direct excision during MMR, then they should be present on both the leading and lagging strands. The presence of these nicks has been recently demonstrated by the high-throughput mapping of DNA strand discontinuities on the *S. cerevisiae* genome.¹¹ Lagging-strand nicks are transient and accumulate only when Okazaki fragment ligation is inhibited, whereas leading-strand nicks are present at higher steady-state levels than lagging-strand nicks in WT cells. The data currently available are not sufficient to determine the absolute numbers of leading- and lagging-strand nicks, as normalization controls required when comparing different DNA libraries were not included¹¹ (H. Ulrich, personal communication). The minimum density of nicks that is required to promote MMR *in vivo* is also not currently known. However, the results of the studies presented here are consistent with the hypothesis that the nicks present on the leading and lagging strands are sufficient to direct strand specificity during MMR. In addition, the length of mitotic gene conversion tracts in yeast, which are mediated by the formation of heteroduplex DNA and subsequent MMR and range from 7.3 to 32.3 kb in length,^{39,40} supports the idea that MMR can catalyze mismatch excision tracts that approach the average distance between replication origins (20–40 kb) in *S. cerevisiae*⁴¹ and, hence, even the low density of leading-strand nicks significantly contribute to MMR. In addition, interactions between MMR and the leading- and lagging-strand replication machinery may also contribute to direct the strand specificity of MMR.^{10,28}

The absolute requirement of a pre-existing nick in MMR reactions reconstituted *in vitro* may explain the fact that Mlh1-Pms1 endonuclease activity is dispensable for many MMR reactions reconstituted *in vitro*, although it is required for MMR *in vivo*.^{30,42} In the context of DNA replication-associated nicks acting as MMR strand-discrimination signals, it can be anticipated that DNA ligase I activity would suppress MMR. This idea is supported by our own results and by the observation that reconstituted MMR reactions using *E. coli* proteins were inhibited by the presence of DNA ligase I, unless *E. coli* exonuclease I was added to the reaction,⁴³ which, in *E. coli*, appears to excise only a small number of nucleotides (<50 nt) from the nick introduced by the Mth endonuclease.⁴⁴ Given the requirement for pre-existing nicks to support MMR, it is unclear what role the eukaryotic Mlh1-Pms1/PMS2 endonuclease plays in MMR *in vivo*. Based on our findings, a possible role for the eukaryotic Mlh1-Pms1/PMS2 endonuclease (with some marginal contribution of Exo1) is to preserve DNA strand discontinuities on the newly replicated strands to direct MMR. The Mlh1-Pms1/PMS2 endonuclease might accomplish this function by introducing additional daughter-strand-specific nicks in the proximity of the mismatch site to convert ligatable nicks into non-ligatable gaps to prevent the premature ligation of the strand discontinuity before MMR is accomplished.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**

- **RESOURCE AVAILABILITY**

- Lead contact
- Materials availability
- Data and code availability

- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

- Yeast strains

- **METHOD DETAILS**

- Plasmids
- Whole cell lysates and western blotting
- Cell synchronization and release
- DNA content analysis
- Mutation rate analysis
- Live cell imaging Pms1 foci
- Detection of Okazaki fragments at the *LYS2* locus
- Whole-cell extracts and chromatin fractions

- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.cub.2020.12.018>.

ACKNOWLEDGMENTS

We would like to thank to Dr. Michael Knop for sharing plasmids and infrastructure, for critical comments to the manuscript, and generous support. Thanks to Dr. Hannah Zhao and Dr. Tobias Schmidt for constructing some plasmids/strains used in this study, Dr. Helle Ulrich for valuable discussions and for sharing plasmids (auxin-degrogen system), and Sandra Ruf and Dr. Nina Papavasiliou for technical support/infrastructure with radioisotopes. R.D.K. and C.D.P. were supported by the NIH grant R01 GM50006 and the Ludwig Institute for Cancer Research. G.X.R., A.K., and H.H. were supported by the Deutsches Krebsforschungszentrum and the Deutsche Forschungsgemeinschaft grant HO-5501-1.

AUTHOR CONTRIBUTIONS

G.X.R., A.K., L.J.P.S.D., T.K., and H.H. performed experiments and analyzed the data. R.D.K., C.D.P., and H.H. conceptualized experiments and interpreted data. T.K. and H.H. supervised experimental work. R.D.K., C.D.P., and H.H. wrote the manuscript, with input from all authors.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: July 17, 2020

Revised: November 10, 2020

Accepted: December 14, 2020

Published: January 7, 2021

REFERENCES

1. Kolodner, R.D., and Marsischky, G.T. (1999). Eukaryotic DNA mismatch repair. *Curr. Opin. Genet. Dev.* 9, 89–96.
2. Jiricny, J. (2013). Postreplicative mismatch repair. *Cold Spring Harb. Perspect. Biol.* 5, a012633.
3. Fishel, R. (2015). Mismatch repair. *J. Biol. Chem.* 290, 26395–26403.
4. Kunkel, T.A., and Erie, D.A. (2015). Eukaryotic mismatch repair in relation to DNA replication. *Annu. Rev. Genet.* 49, 291–313.
5. Dzantiev, L., Constantin, N., Genschel, J., Iyer, R.R., Burgers, P.M., and Modrich, P. (2004). A defined human system that supports bidirectional mismatch-provoked excision. *Mol. Cell* 15, 31–41.

6. Zhang, Y., Yuan, F., Presnell, S.R., Tian, K., Gao, Y., Tomkinson, A.E., Gu, L., and Li, G.M. (2005). Reconstitution of 5c-directed human mismatch repair in a purified system. *Cell* **122**, 693–705.
7. Kadyrov, F.A., Dzantiev, L., Constantin, N., and Modrich, P. (2006). Endonucleolytic function of MutL α in human mismatch repair. *Cell* **126**, 297–308.
8. Smith, C.E., Bowen, N., Graham, W.J., 5th, Goellner, E.M., Srivatsan, A., and Kolodner, R.D. (2015). Activation of *Saccharomyces cerevisiae* Mlh1-Pms1 endonuclease in a reconstituted mismatch repair system. *J. Biol. Chem.* **290**, 21580–21590.
9. Pluciennik, A., Dzantiev, L., Iyer, R.R., Constantin, N., Kadyrov, F.A., and Modrich, P. (2010). PCNA function in the activation and strand direction of MutL α endonuclease in mismatch repair. *Proc. Natl. Acad. Sci. USA* **107**, 16066–16071.
10. Hombauer, H., Srivatsan, A., Putnam, C.D., and Kolodner, R.D. (2011). Mismatch repair, but not heteroduplex rejection, is temporally coupled to DNA replication. *Science* **334**, 1713–1716.
11. Sriramachandran, A.M., Petrosino, G., Méndez-Lago, M., Schäfer, A.J., Batista-Nascimento, L.S., Zilio, N., and Ulrich, H.D. (2020). Genome-wide nucleotide-resolution mapping of DNA replication patterns, single-strand breaks, and lesions by GLOE-seq. *Mol. Cell* **78**, 975–985.e7.
12. Ghodgaonkar, M.M., Lazzaro, F., Olivera-Pimentel, M., Artola-Borán, M., Cejka, P., Reijns, M.A., Jackson, A.P., Plevani, P., Muzi-Falconi, M., and Jiricny, J. (2013). Ribonucleotides misincorporated into DNA act as strand-discrimination signals in eukaryotic mismatch repair. *Mol. Cell* **50**, 323–332.
13. Lujan, S.A., Williams, J.S., Clausen, A.R., Clark, A.B., and Kunkel, T.A. (2013). Ribonucleotides are signals for mismatch repair of leading-strand replication errors. *Mol. Cell* **50**, 437–443.
14. Kim, N., Huang, S.N., Williams, J.S., Li, Y.C., Clark, A.B., Cho, J.E., Kunkel, T.A., Pommier, Y., and Jinks-Robertson, S. (2011). Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. *Science* **332**, 1561–1564.
15. Putnam, C.D. (2016). Evolution of the methyl directed mismatch repair system in *Escherichia coli*. *DNA Repair (Amst.)* **38**, 32–41.
16. Bowman, G.D., O'Donnell, M., and Kuriyan, J. (2004). Structural analysis of a eukaryotic sliding DNA clamp-clamp loader complex. *Nature* **429**, 724–730.
17. Flores-Rozas, H., Clark, D., and Kolodner, R.D. (2000). Proliferating cell nuclear antigen and Msh2p-Msh6p interact to form an active mismatch recognition complex. *Nat. Genet.* **26**, 375–378.
18. Kadyrov, F.A., Holmes, S.F., Arana, M.E., Lukianova, O.A., O'Donnell, M., Kunkel, T.A., and Modrich, P. (2007). *Saccharomyces cerevisiae* MutL α is a mismatch repair endonuclease. *J. Biol. Chem.* **282**, 37181–37190.
19. Goellner, E.M., Smith, C.E., Campbell, C.S., Hombauer, H., Desai, A., Putnam, C.D., and Kolodner, R.D. (2014). PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair. *Mol. Cell* **55**, 291–304.
20. Kawasoe, Y., Tsurimoto, T., Nakagawa, T., Masukata, H., and Takahashi, T.S. (2016). MutS α maintains the mismatch repair capability by inhibiting PCNA unloading. *eLife* **5**, e15155.
21. Tomkinson, A.E., Totty, N.F., Ginsburg, M., and Lindahl, T. (1991). Location of the active site for enzyme-adenylate formation in DNA ligases. *Proc. Natl. Acad. Sci. USA* **88**, 400–404.
22. Subramanian, J., Vijayakumar, S., Tomkinson, A.E., and Arnheim, N. (2005). Genetic instability induced by overexpression of DNA ligase I in budding yeast. *Genetics* **171**, 427–441.
23. Vijayakumar, S., Chapados, B.R., Schmidt, K.H., Kolodner, R.D., Tainer, J.A., and Tomkinson, A.E. (2007). The C-terminal domain of yeast PCNA is required for physical and functional interactions with Cdc9 DNA ligase. *Nucleic Acids Res.* **35**, 1624–1637.
24. Morawska, M., and Ulrich, H.D. (2013). An expanded tool kit for the auxin-inducible degron system in budding yeast. *Yeast* **30**, 341–351.
25. Kubota, T., Katou, Y., Nakato, R., Shirahige, K., and Donaldson, A.D. (2015). Replication-coupled PCNA unloading by the Elg1 complex occurs genome-wide and requires Okazaki fragment ligation. *Cell Rep.* **12**, 774–787.
26. Amin, N.S., Nguyen, M.N., Oh, S., and Kolodner, R.D. (2001). exo1-dependent mutator mutations: model system for studying functional interactions in mismatch repair. *Mol. Cell. Biol.* **21**, 5142–5155.
27. Goellner, E.M., Putnam, C.D., and Kolodner, R.D. (2015). Exonuclease 1-dependent and independent mismatch repair. *DNA Repair (Amst.)* **32**, 24–32.
28. Hombauer, H., Campbell, C.S., Smith, C.E., Desai, A., and Kolodner, R.D. (2011). Visualization of eukaryotic DNA mismatch repair reveals distinct recognition and repair intermediates. *Cell* **147**, 1040–1053.
29. Schmidt, T.T., and Hombauer, H. (2016). Visualization of mismatch repair complexes using fluorescence microscopy. *DNA Repair (Amst.)* **38**, 58–67.
30. Goellner, E.M., Putnam, C.D., Graham, W.J., 5th, Rahal, C.M., Li, B.Z., and Kolodner, R.D. (2018). Identification of Exo1-Msh2 interaction motifs in DNA mismatch repair and new Msh2-binding partners. *Nat. Struct. Mol. Biol.* **25**, 650–659.
31. Nick McElhinny, S.A., Watts, B.E., Kumar, D., Watt, D.L., Lundström, E.B., Burgers, P.M.J., Johansson, E., Chabes, A., and Kunkel, T.A. (2010). Abundant ribonucleotide incorporation into DNA by yeast replicative polymerases. *Proc. Natl. Acad. Sci. USA* **107**, 4949–4954.
32. Tishkoff, D.X., Filosi, N., Gaida, G.M., and Kolodner, R.D. (1997). A novel mutation avoidance mechanism dependent on *S. cerevisiae* RAD27 is distinct from DNA mismatch repair. *Cell* **88**, 253–263.
33. Buckland, R.J., Watt, D.L., Chittoor, B., Nilsson, A.K., Kunkel, T.A., and Chabes, A. (2014). Increased and imbalanced dNTP pools symmetrically promote both leading and lagging strand replication infidelity. *PLoS Genet.* **10**, e1004846.
34. Johnson, C., Gali, V.K., Takahashi, T.S., and Kubota, T. (2016). PCNA retention on DNA into G2/M phase causes genome instability in cells lacking Elg1. *Cell Rep.* **16**, 684–695.
35. Kubota, T., Nishimura, K., Kanemaki, M.T., and Donaldson, A.D. (2013). The Elg1 replication factor C-like complex functions in PCNA unloading during DNA replication. *Mol. Cell* **50**, 273–280.
36. Kang, M.S., Ryu, E., Lee, S.W., Park, J., Ha, N.Y., Ra, J.S., Kim, Y.J., Kim, J., Abdel-Rahman, M., Park, S.H., et al. (2019). Regulation of PCNA cycling on replicating DNA by RFC and RFC-like complexes. *Nat. Commun.* **10**, 2420.
37. Kahli, M., Osmundson, J.S., Yeung, R., and Smith, D.J. (2019). Processing of eukaryotic Okazaki fragments by redundant nucleases can be uncoupled from ongoing DNA replication in vivo. *Nucleic Acids Res.* **47**, 1814–1822.
38. Raghuraman, M.K., Winzeler, E.A., Collingwood, D., Hunt, S., Wodicka, L., Conway, A., Lockhart, D.J., Davis, R.W., Brewer, B.J., and Fangman, W.L. (2001). Replication dynamics of the yeast genome. *Science* **294**, 115–121.
39. Hum, Y.F., and Jinks-Robertson, S. (2017). Mitotic gene conversion tracts associated with repair of a defined double-strand break in *Saccharomyces cerevisiae*. *Genetics* **207**, 115–128.
40. St Charles, J., and Petes, T.D. (2013). High-resolution mapping of spontaneous mitotic recombination hotspots on the 1.1 Mb arm of yeast chromosome IV. *PLoS Genet.* **9**, e1003434.
41. Barberis, M., Spiesser, T.W., and Klipp, E. (2010). Replication origins and timing of temporal replication in budding yeast: how to solve the conundrum? *Curr. Genomics* **11**, 199–211.
42. Tishkoff, D.X., Boerger, A.L., Bertrand, P., Filosi, N., Gaida, G.M., Kane, M.F., and Kolodner, R.D. (1997). Identification and characterization of *Saccharomyces cerevisiae* EXO1, a gene encoding an exonuclease that interacts with MSH2. *Proc. Natl. Acad. Sci. USA* **94**, 7487–7492.
43. Lahue, R.S., Au, K.G., and Modrich, P. (1989). DNA mismatch correction in a defined system. *Science* **245**, 160–164.

44. Liu, J., Lee, R., Britton, B.M., London, J.A., Yang, K., Hanne, J., Lee, J.-B., and Fishel, R. (2019). MutL sliding clamps coordinate exonuclease-independent *Escherichia coli* mismatch repair. *Nat. Commun.* *10*, 5294.
45. Schmidt, T.T., Sharma, S., Reyes, G.X., Kolodziejczak, A., Wagner, T., Luke, B., Hofer, A., Chabes, A., and Hombauer, H. (2020). Inactivation of folypolyglutamate synthetase Met7 results in genome instability driven by an increased dUTP/dTTP ratio. *Nucleic Acids Res.* *48*, 264–277.
46. Schmidt, T.T., Reyes, G., Gries, K., Ceylan, C.U., Sharma, S., Meurer, M., Knop, M., Chabes, A., and Hombauer, H. (2017). Alterations in cellular metabolism triggered by *URA7* or *GLN3* inactivation cause imbalanced dNTP pools and increased mutagenesis. *Proc. Natl. Acad. Sci. USA* *114*, E4442–E4451.
47. Sikorski, R.S., and Hieter, P. (1989). A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* *122*, 19–27.
48. Christianson, T.W., Sikorski, R.S., Dante, M., Shero, J.H., and Hieter, P. (1992). Multifunctional yeast high-copy-number shuttle vectors. *Gene* *110*, 119–122.
49. Lau, P.J., Flores-Rozas, H., and Kolodner, R.D. (2002). Isolation and characterization of new proliferating cell nuclear antigen (POL30) mutator mutants that are defective in DNA mismatch repair. *Mol. Cell. Biol.* *22*, 6669–6680.
50. Janke, C., Magiera, M.M., Rathfelder, N., Taxis, C., Reber, S., Maekawa, H., Moreno-Borchart, A., Doenges, G., Schwob, E., Schiebel, E., and Knop, M. (2004). A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettes. *Yeast* *21*, 947–962.
51. Sheu, Y.J., and Stillman, B. (2006). Cdc7-Dbf4 phosphorylates MCM proteins via a docking site-mediated mechanism to promote S phase progression. *Mol. Cell* *24*, 101–113.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-MYC (clone 4A6)	Millipore	Cat# 05-724; RRID: AB_11211891
Rat monoclonal anti-HA (clone 3F10)	Roche	Cat# 3F10; RRID: AB_2314622
Rabbit polyclonal anti-Clb2	Santa Cruz	Cat# sc-9071; RRID: AB_667962
Mouse monoclonal anti-PCNA	Abcam	Cat# ab70472; RRID: AB_2160644
Rabbit polyclonal anti-Rnr3	Agrisera	Cat# AS09 574; RRID: AB_1966947
Rat monoclonal anti-Tubulin & Rnr4 (clone YL1/2)	Millipore	Cat# MAB1864; RRID: AB_2210391
Mouse monoclonal anti-Histone H3	Abcam	Cat# ab46765; RRID: AB_880439
Guinea pig polyclonal anti-Sic1	⁴⁵	N/A
Chemicals, peptides, and recombinant proteins		
α -factor	GenScript	RP01002
Nocodazole	TargetMol	T2802
α - ³² P-dCTP	PerkinElmer	NEG013H
Zymolyase-100T	US Biological	Z1005
Restriction endonucleases (<i>Bgl</i> II, <i>Bam</i> HI, <i>Xho</i> I, <i>Not</i> I, <i>Sal</i> I, <i>Eco</i> R V, <i>Kpn</i> I)	New England Biolabs	N/A
Sytox Green	Thermo Fisher	S7020
Hybond N ⁺ membrane	Amersham GE Healthcare	RPN303B
3-Indoleacetic acid (Auxin)	Sigma Aldrich	I2886
Critical commercial assays		
Megaprime DNA labeling system	Amersham GE Healthcare	RPN1606
PureGene Yeast/Bact. kit	QIAGEN	158567
Experimental models: organisms/strains		
<i>MATα ura3-52 leu2Δ1 trp1Δ63 his3Δ200 hom3-10 lys2-10A</i>	²⁶	RDKY3686
<i>MATα ura3-52 leu2Δ1 trp1Δ63 his3Δ200 hom3-10 lys2-10A</i>	²⁸	RDKY5964
RDKY5964 <i>msh2::HIS3</i>	⁴⁶	HHY6505
RDKY5964 <i>elg1::HIS3</i>	this study	HHY8074
RDKY5964 <i>elg1::HIS3 exo1::hphNT1</i>	this study	HHY6828
RDKY5964 <i>exo1::hphNT1</i>	⁴⁶	HHY1794
RDKY5964 <i>exo1::hphNT1 LEU2.pol30-K217E</i>	this study	HHY6035
RDKY5964 <i>exo1-F447A-F448A-Δ571-702.kanMX4</i>	this study	HHY7017
RDKY5964 <i>exo1-F447A-F448A-Δ571-702.kanMX4 natNT2.pGPD-CDC9</i>	this study	HHY7010
RDKY5964 <i>natNT2.pGPD-CDC9</i>	this study	HHY6770
RDKY5964 <i>natNT2.pGPD-CDC9-9MYC.HIS3</i>	this study	HHY8138
RDKY5964 <i>natNT2.pGPD-CDC9 exo1::hphNT1</i>	this study	HHY6772
RDKY5964 <i>natNT2.pGPD-CDC9 msh2::HIS3</i>	this study	HHY6899
RDKY5964 <i>kanMX4.pGPD-CDC9 rad27::hphNT1</i>	this study	HHY7094
RDKY5964 <i>natNT2.pGPD-ELG1</i>	this study	HHY8075
RDKY5964 <i>natNT2.pGPD-ELG1 exo1::hphNT1</i>	this study	HHY6837
RDKY5964 <i>pol2-M644G.natNT2</i>	⁴⁶	HHY1993
RDKY5964 <i>kanMX4.pGPD-CDC9 natNT2.pGPD-ELG1</i>	this study	HHY6834
RDKY5964 <i>kanMX4.pGPD-CDC9 exo1::hphNT1 natNT2.pGPD-ELG1</i>	this study	HHY6831
RDKY5964 <i>kanMX4.pGPD-CDC9 elg1::HIS3</i>	this study	HHY6913
RDKY5964 <i>kanMX4.pGPD-CDC9 exo1::hphNT1 elg1::HIS3</i>	this study	HHY6825
RDKY5964 <i>LEU2.pol30-C81R</i>	this study	HHY3234

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
RDKY5964 <i>LEU2.pol30-K217E</i>	this study	HHY7555
RDKY5964 <i>lys2::kl-TRP1</i>	this study	HHY7586
RDKY5964 <i>natNT2.pGPD-CDC9 LEU2.pol30-K217E</i>	this study	HHY7362
RDKY5964 <i>pms1-A99V</i>	this study	HHY5554
RDKY5964 <i>rad27::hphNT1</i>	this study	HHY5082
RDKY5964 <i>natNT2.pGPD-CDC9 pms1-A99V</i>	this study	HHY7375
RDKY5964 <i>natNT2.pCib2-Cib2_(1-181, L26A)-MSH6-9MYC.hphNT1 msh3::kanMX4 pGAL-his3::intron::cβ2/cβ2::URA3</i>	¹⁰	RDKY7676
RDKY5964 <i>natNT2.pCib2-Cib2_(1-181, L26A)-3MYC-CDC9</i>	this study	HHY6701
RDKY5964 <i>natNT2.pCib2-Cib2_(1-181, L26A)-MSH6 msh3::HIS3 natNT2.pCib2-Cib2_(1-181, L26A)-3MYC-CDC9</i>	this study	HHY4983
RDKY5964 <i>hphNT1.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1</i>	this study	HHY7192
RDKY5964 <i>kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1 exo1::hphNT1</i>	this study	HHY7202
RDKY5964 <i>hphNT1.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1 lys2::kl-TRP1 lys2-10A_{LATE}.kanMX4</i>	this study	HHY7894
RDKY5964 <i>CDC9-3MYC.HIS3 PMS1-6HA.hphNT1</i>	this study	HHY7972
RDKY5964 <i>natNT2.pCib2-Cib2_(1-181, L26A)-3MYC-CDC9 kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1</i>	this study	HHY7708
RDKY5964 <i>natNT2.pCib2-Cib2_(1-181, L26A)-3MYC-CDC9 mlh1::kl-TRP1</i>	this study	HHY7768
RDKY5964 <i>natNT2.pCib2-Cib2_(1-181, L26A)-3MYC-CDC9 kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1-6HA.HIS3</i>	this study	HHY7979
RDKY5964 <i>kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1 exo1::hphNT1 natNT2.pCib2-Cib2_(1-181, L26A)-3MYC-CDC9</i>	this study	HHY7660
RDKY5964 <i>cdc9-F44A-F45A</i>	this study	HHY7774
RDKY5964 <i>kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1 cdc9-F44A-F45A</i>	this study	HHY7839
RDKY5964 <i>kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1 natNT2.pGPD-CDC9</i>	this study	HHY7715
RDKY5964 <i>kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1 exo1::hphNT1 cdc9-F44A-F45A</i>	this study	HHY7835
RDKY5964 <i>kanMX4.pCib2-Cib2_(1-181, L26A)-3MYC-PMS1 exo1::hphNT1 elg1::HIS3</i>	this study	HHY7672
RDKY5964 <i>leu2::ADH-AFB2.hphNT1 CDC9-9MYC-AID*.natNT2</i>	this study	HHY8076
RDKY5964 <i>PMS1-4GFP.kanMX6</i>	²⁸	RDKY7588
RDKY5964 <i>exo1::hphNT1 PMS1-4GFP.kanMX6</i>	²⁸	RDKY7544
RDKY5964 <i>elg1::HIS3 PMS1-4GFP.kanMX6</i>	this study	HHY8077
RDKY5964 <i>elg1::HIS3 exo1::hphNT1 PMS1-4GFP.kanMX6</i>	this study	HHY6982
RDKY5964 <i>natNT2.pGPD-CDC9 PMS1-4GFP.kanMX6</i>	this study	HHY8078
RDKY5964 <i>exo1::hphNT1 natNT2.pGPD-CDC9 PMS1-4GFP.kanMX6</i>	this study	HHY6895
RDKY5964 <i>elg1::HIS3 natNT2.pGPD-CDC9 PMS1-4GFP.kanMX6</i>	this study	HHY6987
RDKY5964 <i>elg1::HIS3 exo1::hphNT1 natNT2.pGPD-CDC9 PMS1-4GFP.kanMX6</i>	this study	HHY6978
RDKY5964 <i>natNT2.pGPD-ELG1 PMS1-4GFP.kanMX6</i>	this study	HHY7499
RDKY5964 <i>exo1::hphNT1 natNT2.pGPD-ELG1 PMS1-4GFP.kanMX6</i>	this study	HHY7505
RDKY5964 <i>kanMX4.pGPD-CDC9 natNT2.pGPD-ELG1 PMS1-4GFP.kanMX6</i>	this study	HHY7142
RDKY5964 <i>exo1::hphNT1 kanMX4.pGPD-CDC9 natNT2.pGPD-ELG1 PMS1-4GFP.kanMX6</i>	this study	HHY7132

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Recombinant DNA		
<i>URA3</i> integrative plasmid (pop-in/pop-out) Amp ^R	47	pRS306
<i>ori</i> 2 μ <i>URA3</i> Amp ^R	48	pRS426
<i>pCH1572-poi30-C81R-LEU2</i> (one-step integrative plasmid) Amp ^R	49	pRDK926
<i>kanMX4</i> Amp ^R	50	<i>pFA6a-kanMX4</i>
<i>hphNT1</i> Amp ^R	50	<i>pFA6a-hphNT1</i>
<i>natNT2</i> Amp ^R	50	<i>pFA6a-natNT2</i>
<i>pGPD kanMX4</i> Amp ^R	50	pYM-N14
<i>pGPD natNT2</i> Amp ^R	50	pYM-N15
C-terminal 3xMYC <i>HIS3MX6</i> Amp ^R	50	pYM5
C-terminal 6xHA <i>hphNT1</i> Amp ^R	50	pYM16
<i>pCH1572-poi30-K217E-LEU2</i> (one-step integrative plasmid) Amp ^R	This study	pHHB252
<i>pRS426-CDC9</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1152
<i>pRS426-cdc9-F44A-F45A</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1163
<i>pRS426-cdc9-K419A</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1164
<i>pRS426-cdc9-K598A</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1165
<i>pRS306-cdc9-F44A-F45A URA3</i> integrative Amp ^R	This study	pHHB1274
<i>pRS306-exo1-F447A-F448A URA3</i> integrative Amp ^R	This study	pHHB1187
<i>pSM409-Nat-AID*-9MYC</i> Amp ^R	24	<i>pNat-AID*-9MYC</i>
<i>pFA6a-hphNT1-pADH-AFB2</i> Amp ^R	This study	pHHB699
<i>pCLB2-3xMYC-(GA)₅-CLB2_(1-181+L26A)-kanMX4</i> Amp ^R	This study	pHHB1220
<i>pCLB2-3xMYC-(GA)₅-CLB2_(1-181+L26A)-hphNT1</i> Amp ^R	This study	pHHB1221
<i>pCLB2-3xMYC-(GA)₅-CLB2_(1-181+L26A)-natNT2</i> Amp ^R	This study	pHHB1222
<i>pRS426-CDC9-HA</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1194
<i>pRS426-cdc9-F44A-F45A-HA</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1195
<i>pRS426-cdc9-K419A-HA</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1196
<i>pRS426-cdc9-K598A-HA</i> 2 μ <i>URA3</i> Amp ^R	This study	pHHB1197
Software and algorithms		
SoftWoRx 6.1.1 Release 5	Applied Precision	N/A
SigmaPlot version 10	Systat Software	N/A
ImageJ, FIJI	ImageJ	https://fiji.sc
Lasergene 15.1.0	DNASTAR	N/A

RESOURCE AVAILABILITY

Lead contact

Information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Hans Hombauer (h.hombauer@zmbh.uni-heidelberg.de).

Materials availability

Plasmids and yeast strains generated in this study can be obtained through the Lead Contact.

Data and code availability

The published article includes all datasets generated or analyzed during this study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Yeast strains

All *S. cerevisiae* strains used in this study are listed in the [Key resources table](#) and were derivatives of the S288C strains RDKY3686²⁶ (*MAT α ura3-52 leu2 Δ 1 trp1 Δ 63 his3 Δ 200 hom3-10 lys2-10A*) or RDKY5964²⁸ (*MAT α* version of RDKY3686). Strains were grown at 30°C in yeast extract-peptone-dextrose media (YPD) or dextrose synthetic dropout media. Arginine dropout media containing

60 mg/L of canavanine was used for selecting canavanine resistant cells (Can^R). Gene deletions, gene tagging, and promoter replacements were done using standard PCR-based recombination methods,⁵⁰ followed by confirmation by PCR and sequencing. Strains containing two or more genetic modifications were usually obtained by mating and sporulation. All experiments were performed with at least two independent biological isolates. With exception of the *pol30-C81R* and *pol30-K217E* alleles described below, point mutations were introduced at their chromosomal loci with *URA3*-integrative vectors using pop-in/pop-out strategies, and were confirmed by sequencing. Strains containing the *lys2-10A_{LATE}* frameshift reporter (replicated during late S phase) were previously described.¹⁰

The *pol30-C81R* and *pol30-K217E* alleles were introduced at the *POL30* locus by a one-step replacement after transformation with *Sac* I-digested *LEU2* plasmids pRDK926⁴⁹ or pHHB252, respectively.

The *cdc9-FFAA* mutant allele that contains two consecutive phenylalanine-alanine substitutions (F44A and F45A) was introduced at the *CDC9* chromosomal locus using pop-in/pop-out strategy with the integrative plasmid pHHB1274 linearized with *Bgl* II.

Strains containing the *pms1-A99V* mutation were obtained after mating with RDKY4177²⁶ (*MATa ura3-52 leu2Δ1 trp1Δ63 hom3-10 lys2-10A exo1::URA3 pms1-A99V*) and sporulation.

The strain expressing the *exo1-F447A-F448A-Δ571-702* allele (referred in the main text as *exo1-FFAA-Δ571-702*) was generated in two steps: (1) the *exo1-F447A-F448A* point mutations were introduced by pop-in/pop-out strategy with the pHHB1187 integrative vector linearized with *Bgl* II; and (2) this strain was transformed with a PCR cassette carrying a *kanMX4* module that introduces a STOP codon in *Exo1*, right after codon 570.

The strain HHY8076, which expresses an auxin-inducible degron fused to the chromosomal copy of *CDC9* (*CDC9-9MYC-AID*-natNT2*) used for *cdc9* plasmid complementation experiments (Figure S1A), was constructed by PCR-mediated recombination with the plasmid pNat-AID*-9MYC.²⁴ The strain HHY8076 also contains a *pADH-AFB2.hphNT1* cassette (integrated at the *LEU2* locus) that expresses the *AFB2* F-box gene required for auxin-induced protein degradation. Integration of this cassette was performed by PCR-mediated recombination with a PCR product generated using the plasmid pHHB699 as template and S1 and S2 primers.⁵⁰

METHOD DETAILS

Plasmids

Plasmids used in this study are listed in the [Key resources table](#). The pHHB1220-1222 plasmids were used as template DNAs in PCR reactions to amplify the *G2/M*-tag (*pCib2-Cib2_(1-181+L26A)*) linked to a selectable marker cassette (*kanMX4*, *hphNT1* and *natNT2*, respectively). The *G2/M*-tag present in these three plasmids is identical to that contained in pRDK1598¹⁰ plasmid, with the exception that these constructs contain a triple MYC-tag and a (GA)₅ linker after the *Cib2* N terminus (1-181 aa + L26A). These new plasmids are now compatible with S1 and S4 primer design.⁵⁰

High copy number plasmids (*URA3*, 2 μ , Amp^R) harboring WT-*CDC9*, *cdc9-FFAA*, *cdc9-K419A* and *cdc9-K598A* were constructed using the pRS426⁴⁸ backbone, and correspond to pHHB1152, pHHB1163, pHHB1164 and pHHB1165, respectively. These *CDC9/cdc9* overexpression plasmids contain the full-length *CDC9* gene (including 1 kb of the promoter sequence and 300 bp of the terminator region) cloned into the *Bam*H I and *Xho* I sites present in the pRS426 polylinker. *Cdc9* mutant alleles were generated by site-directed mutagenesis. In addition, we constructed another set of plasmids that were almost identical to pHHB1152, pHHB1163, pHHB1164 and pHHB1165 except that they harbor the WT-*CDC9*, *cdc9-FFAA*, *cdc9-K419A* and *cdc9-K598A* alleles fused to an HA-tag at the C terminus, and are named pHHB1194, pHHB1195, pHHB1196 and pHHB1197, respectively.

The pHHB252 plasmid used to integrate the *pol30-K217E* allele was constructed as follows. First, the plasmid pRDK925⁴⁹ containing the *pol30-C22Y* mutant allele was reverted back to WT-*POL30* by site-directed mutagenesis resulting in pHHB247. Next, the *pol30-K217E* mutation was introduced by site-directed mutagenesis resulting in pHHB252.

The pHHB1274 plasmid used to integrate the *cdc9-FFAA* mutation was constructed as follows. The 3.6 kb *Bam*H I-*Xho* I fragment from pHHB1163, which contains the *cdc9-F44A-F45A* allele, was subcloned into the *Bam*H I-*Xho* I sites in pRS306,⁴⁷ resulting in pHHB1274.

The pHHB1187 plasmid used to integrate the *exo1-F447A-F448A* mutant allele was constructed as follows. First, the WT-*EXO1* gene (including 500 bp of the promoter and 253 bp of the terminator) was amplified by PCR from a WT yeast strain (RDKY5964)²⁸ and cloned into the *Hind* III and *Xho* I sites in pRS426, resulting in pHHB245. Next, the *exo1-F447A-F448A* mutations were introduced in pHHB245 by site-directed mutagenesis resulting in pHHB1186. Last, the 2.9 kb *Not* I-*Xho* I fragment from pHHB1186 was subcloned into the *Not* I-*Sal* I sites in pRS306, resulting in pHHB1187.

The pHHB699 plasmid harboring the *pADH-AFB2.hphNT1* cassette (used in auxin-induced protein degradation experiments) was constructed by subcloning the 2.5 kb *Sal* I fragment from pRS303-*ADH-AFB2* into the *Sal* I site in pFA6a-*hphNT1*,⁵⁰ resulting in pHHB699. Further analysis of this plasmid revealed that the *AFB2* gene is in the same orientation as the *hphNT1* resistance gene.

Whole cell lysates and western blotting

S. cerevisiae whole cell lysates and western blotting analysis were performed as described.²⁸ Antibodies including catalog number and manufacturer used in this study were: MYC (4A6, Millipore), HA (3F10, Roche), *Cib2* (sc-9071, Santa Cruz), PCNA (ab70472, Abcam), Rnr3 (AS09574, Agrisera), tubulin-Rnr4 (YL1/2, Sigma), Histone H3 (ab46765, Abcam) and Sic1 (previously described⁴⁵). In

order to detect PCNA more efficiently with the anti-PCNA antibody (ab70472, Abcam), the membrane was incubated in a mild stripping buffer (0.2 M glycine pH 2.2, 0.1% SDS, 1% Tween 20) prior to blocking.

Cell synchronization and release

S. cerevisiae cells were synchronized by G1-arrest using a 3-hour incubation in the presence of 10 $\mu\text{g/ml}$ α -factor (GenScript). For release from G1-arrest, cells were washed with water and resuspended in YPD medium containing 15 $\mu\text{g/ml}$ nocodazole (Sigma-Aldrich) to prevent cells from entering a second G1 and S phase.

DNA content analysis

Analysis of DNA content in yeast cells was done as previously described.¹⁰

Mutation rate analysis

The *lys2-10A* and *hom3-10* frameshift reversion assays, and the *CAN1* inactivation assay were used to quantify mutation rates using fluctuation analysis as previously described.²⁶ Statistical significance was evaluated by calculating 95% confidence intervals.

Live cell imaging Pms1 foci

Exponentially growing cells were washed, resuspended and placed on agar pads, covered with a coverslip and sealed with valap (1:1:1 mixture of Vaseline, lanolin and paraffin by weight). Cells were imaged at 30°C using a DeltaVision RT (Applied Precision) based on an inverted microscope (IX70, Olympus) with a camera (CoolSNAP HQ2, Photometrics) and a Plan-Apo 100x (1.4 NA) oil immersion objective lens (Olympus). 20 Z stacks spaced 0.3 μm were deconvolved using SoftWoRx software and projected using the maximum intensity projection.

Detection of Okazaki fragments at the *LYS2* locus

Genomic DNA from logarithmic cells, synchronized in G1 phase or G1-synchronized and released for the indicated times, was isolated using the PureGene kit (QIAGEN). Approximately, 6×10^8 cells were used for each time point. DNA was resuspended in 30 μL TE buffer (10 mM Tris pH 7.5, 0.1 mM EDTA) and kept at 4°C or used immediately for Southern blot analysis. Quality, purity and concentration of the DNA were evaluated by gel electrophoresis. Then, equal amounts of purified genomic DNA were treated with *EcoRV* overnight at 37°C, mixed with loading dye containing 1 M urea, heated at 86°C for 5 min, then loaded in 1.2% agarose gels and resolved under urea/heat denaturing conditions; both the gel and running buffer contained 1 M urea and electrophoresis was for 5 hours at 80 V. The gels were blotted to Hybond N⁺ membrane (Amersham GE Healthcare Life Science) by capillary blotting. Hybridization with 20 ng of ³²P-radiolabelled probe was done in 2xSSC, 7% SDS and shared salmon sperm DNA (0.2 mg/ml) at 58°C. To prepare the radiolabeled probe, the pHHB762 plasmid that harbors the *LYS2* genomic sequence (including 600 bp of the promoter sequence and 160 bp of the 3' UTR) was digested with *Kpn* I and *Xho* I and the 1.2 kb fragment was purified and labeled with α -³²P-dCTP using the Megaprime DNA labeling system (Amersham GE Healthcare Life Science). The probe was purified from unincorporated nucleotides using Illustra microspin G-50 columns (Amersham GE Healthcare Life Science). Before hybridization the probe was denatured 5 min at 95°C and placed on ice before adding to the hybridization buffer. Membranes were exposed to a phospho-screen, and the radioactive signal was detected with a Phosphor Imaging module (Sapphire Biomolecular Imager).

Whole-cell extracts and chromatin fractions

Whole-cell extracts (WCEs) and chromatin enriched-fractions were prepared essentially as described previously.⁵¹ Approximately 3×10^8 logarithmically growing cells were harvested and resuspended in 1 mL of prespheroplasting buffer (100 mM PIPES/KOH, pH 9.4, 10 mM DTT, 0.1% sodium azide) then incubated for 10 min on ice. Cells were then incubated in 1 mL of spheroplasting buffer (50 mM $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$, pH 7.4, 0.8 M sorbitol, 10 mM DTT, 0.1% sodium azide) containing 200 $\mu\text{g/ml}$ Zymolyase-100T at 30°C for 10 min with occasional mixing. Spheroplasts were washed twice with 1 mL of ice-cold wash buffer (20 mM $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$, pH 6.5, 0.8 M sorbitol, 1 mM MgCl_2 , 1 mM DTT, 20 mM β -glycerophosphate, 1 mM PMSF, protease inhibitor tablets (EDTA free, Roche)). Spheroplasts were resuspended in 3 vol. of EB buffer (50 mM HEPES/KOH, pH 7.5, 100 mM KCl, 2.5 mM MgCl_2 , 0.1 mM ZnSO_4 , 2 mM NaF, 0.5 mM spermidine, 1 mM DTT, 20 mM β -glycerophosphate, 1 mM PMSF, protease inhibitor tablets (EDTA free)), lysed by addition of Triton X-100 to 0.25%, and incubated on ice for 10 min. WCEs were prepared by mixing 20 μL of the lysate with 20 μL of 2 \times Tris-Glycine SDS Sample Buffer and incubated for 3 min at 85°C. The remaining lysate was laid over on 0.4 mL of EBX-S buffer (EB buffer, 30% sucrose, 0.25% Triton X-100), and spun at 12,000 rpm for 10 min at 4°C. The chromatin pellet was washed in 0.5 mL of EBX buffer (EB buffer, 0.25% Triton X-100) and spun at 10,000 rpm for 2 min at 4°C. The chromatin pellet was resuspended in 50 μL of 2 \times Tris-Glycine SDS Sample Buffer and incubated for 3 min at 85°C. To detect PCNA, 10 μL of chromatin fractions were analyzed in SDS-PAGE, followed by western blot with anti-PCNA antibody (ab70472, Abcam).

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis for mutation rates as well as analysis of Pms1 foci were performed in SigmaPlot. *P*-values were calculated using the Mann-Whitney rank sum test and were indicated on the graphs and represent statistical significance of the difference between

the two data groups. Mutation rates analysis in *S. cerevisiae* were determined using two independent biological isolates and a total of at least 14 independent cultures. The mutation rate data shown in the graphs correspond to median rates for the indicated mutational reporter, the error bars correspond to the 95% confidence intervals. Quantification of Pms1 foci abundance was performed with at least 1000 cells per genotype, using three independent biological isolates. Data presented in [Figure 1B](#) shows the average of the percentage of cells containing foci, error bars indicate SEM. In [Figure 3C](#) data is presented as box-plots with whiskers and dots represent outliers. Black and red lines inside the box represent the median and average of cells with foci, respectively.

Current Biology, Volume 31

Supplemental Information

Ligation of newly replicated DNA controls

the timing of DNA mismatch repair

Gloria X. Reyes, Anna Kolodziejczak, Lovely Jael Paul Solomon Devakumar, Takashi Kubota, Richard D. Kolodner, Christopher D. Putnam, and Hans Hombauer




Figure S1. Validation of the function of plasmid-borne *CDC9* alleles and characterization of *CDC9* overexpressing strains. Related to Figure 1, 2 and 3 and Table S2.

(A) High copy number vectors were tested for their ability to complement a chromosomally encoded version of *CDC9* fused to the auxin-inducible degron. Plasmids expressing WT *CDC9* or *cdc9-FFAA*, which encodes a version of Cdc9 that cannot interact with PCNA *in vitro*, allowed cells to grow on YPD containing 4 mM auxin. In contrast, an empty vector (ev) control and both ligase-defective mutant alleles (*cdc9-K419A* and *cdc9-K598A*) could not. (B) Western blot analysis indicating expression levels of WT-Cdc9 or *cdc9* mutant alleles (tagged with a C-terminal HA-tag) expressed from high copy number plasmids. An antibody against tubulin was used as a loading control. (C) Western blot analysis showing Cdc9 protein levels in yeast strains expressing the *CDC9* gene at endogenous levels (endog. levels) or under the control of the strong constitutive promoter (pGPD), resulting in Cdc9-overexpression (*CDC9-OE*). To facilitate the visualization of the Cdc9 protein, the chromosomal *CDC9* gene was tagged at the C-terminus with a 9xMYC tag. (D) Abundance of PCNA in whole cell extracts (WCE) and chromatin-enriched fractions (chromatin) in the indicated mutant strains. Strains carrying the *pol30-C81R* and *elg1 Δ* mutations, which were previously shown to have reduced or increased chromatin-bound PCNA levels, respectively [S1, S2], were included as controls. Inactivation of Elg1 results in an increase of Sumo-PCNA as previously reported [S2, S3]. Histone H3 was used as a chromatin-loading control.




Figure S2. *CDC9* alleles with delayed (*G2/M-CDC9*) or reduced (*cdc9-FFAA*) ligase activity results in accumulation of unprocessed Okazaki fragments at the *LYS2* locus. Related to Figure 4.

(A) Diagram showing the strategy used for the generation of the P^{32} -probe used for detection of Okazaki fragments at the *LYS2* locus by Southern blotting. (B) Southern blot analysis used for the detection of Okazaki fragments at the *LYS2* locus in WT and the *G2/M-CDC9* or the *cdc9-FFAA* mutant strains either growing logarithmically (log), arrested in G1 phase by alpha-factor (α -F), synchronized in S phase (30 min release after α -F) or synchronized in G2/M phase (90 min release after α -F). A *LYS2* deficient strain (*lys2Δ*) was used as a control for *LYS2*- P^{32} probe specificity. As a positive control, a plasmid harboring the *LYS2* gene was digested with either *EcoR* V (detected as a 3.7 kb fragment) or *Kpn* I +*Nhe* I +*Xho* I (detected as 0.5 and 0.7 kb fragments) and pooled (*pLYS2+RE**).




Figure S3. Delayed ligation of Okazaki fragments in the *G2/M-CDC9* mutant results in activation of the DNA damage response and accumulation of cells in S phase.

Related to Figure 4.

(A, B) Whole cell lysates of the indicated strains were analyzed by western blotting with antibodies recognizing DNA damage-inducible ribonucleotide reductase subunits Rnr3 and Rnr4 [S4, S5]. A mutant strain expressing the *pol2-M644G* allele that results in activation of the DNA damage response [S6, S7] was included as a positive control. * denotes a cross-reacting protein. Tubulin was used as a loading control. (C) DNA content analysis of the indicated logarithmically growing strains.

Relevant genotype	Mutation Rate (fold increase) [*]		
	Ura ⁺ Lys ⁺	Ura ⁺ Thr ⁺	Ura ⁺ Can ^R
wild-type + pRS426	1.1 [0.8-2.8] x 10 ⁻⁷ (1)	1.5 [0.8-2.6] x 10 ⁻⁸ (1)	7.7 [4.4-16.8] x 10 ⁻⁷ (1)
wild-type + pRS426- <i>CDC9</i>	1.0 [0.5-1.8] x 10 ⁻⁶ (9)	6.8 [3.3-11.4] x 10 ⁻⁸ (4)	2.0 [1.5-2.5] x 10 ⁻⁶ (3)
<i>exo1Δ</i> + pRS426	3.0 [1.3-6.1] x 10 ⁻⁷ (3)	1.6 [0.6-2.2] x 10 ⁻⁸ (1)	2.5 [2.2-3.2] x 10 ⁻⁶ (3)
<i>exo1Δ</i> + pRS426- <i>CDC9</i>	1.0 [0.7-1.6] x 10 ⁻⁴ (940)	2.2 [1.8-3.1] x 10 ⁻⁶ (144)	9.4 [6.2-21.7] x 10 ⁻⁶ (12)
<i>exo1Δ</i> + pRS426- <i>cdc9-F44A-F45A</i>	4.1 [2.2-8.1] x 10 ⁻⁶ (38)	6.4 [4.7-11.9] x 10 ⁻⁸ (4)	3.6 [2.8-4.4] x 10 ⁻⁶ (5)
<i>exo1Δ</i> + pRS426- <i>cdc9-K419A</i>	2.7 [1.3-4.6] x 10 ⁻⁷ (2)	1.6 [1.3-2.6] x 10 ⁻⁸ (1)	2.5 [1.8-3.7] x 10 ⁻⁶ (3)
<i>exo1Δ</i> + pRS426- <i>cdc9-K598A</i>	4.1 [2.6-9.5] x 10 ⁻⁷ (4)	1.8 [0.8-3.2] x 10 ⁻⁸ (1)	2.6 [1.9-3.4] x 10 ⁻⁶ (3)

Table S1. Mutation rate analysis in strains overexpressing WT-*CDC9* and *cdc9* mutant alleles. Related to Figure 1A.

^{*} Median rates of *lys2-10A* (Ura⁺ Lys⁺) and *hom3-10* (Ura⁺ Thr⁺) frameshift reversion and inactivation of *CAN1* gene (Ura⁺ Can^R) assays with 95% confidence interval in square brackets and fold increase relative to the wild-type in parentheses.

Relevant genotype	Mutation Rate (fold increase) [*]		
	Lys ⁺	Thr ⁺	Can ^R
wild-type	1.5 [0.8-2.2] x 10 ⁻⁸ (1)	2.1 [1.4-3.2] x 10 ⁻⁹ (1)	7.2 [5.7-9.0] x 10 ⁻⁸ (1)
<i>msh2Δ</i>	9.9 [8.1-10.8] x 10 ⁻⁵ (6771)	6.3 [5.2-12.8] x 10 ⁻⁶ (3053)	5.4 [4.4-7.2] x 10 ⁻⁶ (75)
<i>CDC9-OE</i>	6.0 [4.6-6.9] x 10 ⁻⁸ (4)	5.4 [4.2-6.3] x 10 ⁻⁹ (3)	1.1 [0.8-1.4] x 10 ⁻⁷ (2)
<i>exo1Δ</i>	9.8 [6.9-22.8] x 10 ⁻⁸ (7)	5.2 [3.3-7.9] x 10 ⁻⁹ (3)	4.3 [2.9-8.7] x 10 ⁻⁷ (6)
<i>CDC9-OE exo1Δ</i>	6.1 [3.4-12.1] x 10 ⁻⁶ (416)	3.7 [2.8-5.7] x 10 ⁻⁷ (180)	1.3 [1.1-1.5] x 10 ⁻⁶ (18)
<i>exo1-FFAA-Δ571-702</i>	3.6 [2.9-5.3] x 10 ⁻⁸ (2)	2.8 [2.0-4.7] x 10 ⁻⁹ (1)	8.2 [6.3-17.5] x 10 ⁻⁸ (1)
<i>CDC9-OE exo1-FFAA-Δ571-702</i>	6.7 [4.4-10.8] x 10 ⁻⁶ (457)	3.4 [1.6-5.6] x 10 ⁻⁷ (163)	1.7 [0.7-2.8] x 10 ⁻⁶ (24)
<i>pol30-K217E</i>	1.2 [0.8-2.4] x 10 ⁻⁶ (85)	4.1 [3.5-6.4] x 10 ⁻⁸ (20)	5.1 [3.9-10.7] x 10 ⁻⁷ (7)
<i>pol30-K217E exo1Δ</i>	5.5 [4.8-7.0] x 10 ⁻⁵ (3772)	2.7 [1.6-4.2] x 10 ⁻⁶ (1317)	7.1 [3.7-10.8] x 10 ⁻⁶ (99)
<i>CDC9-OE pol30-K217E</i>	6.9 [6.1-9.5] x 10 ⁻⁶ (474)	2.1 [1.5-3.1] x 10 ⁻⁷ (103)	1.2 [1.0-1.3] x 10 ⁻⁶ (16)
<i>CDC9-OE exo1Δ pol30-K217E</i>	3.0 [2.2-4.2] x 10 ⁻⁴ (20751)	2.1 [1.4-3.3] x 10 ⁻⁵ (10089)	2.0 [1.4-3.1] x 10 ⁻⁵ (278)
<i>pms1-A99V</i>	4.0 [1.7-7.3] x 10 ⁻⁷ (27)	6.3 [4.0-9.7] x 10 ⁻⁸ (30)	4.0 [1.9-7.5] x 10 ⁻⁷ (6)
<i>CDC9-OE pms1-A99V</i>	7.9 [3.4-12.4] x 10 ⁻⁶ (543)	1.4 [0.7-2.2] x 10 ⁻⁶ (688)	1.5 [1.1-1.7] x 10 ⁻⁶ (20)
<i>CDC9-OE msh2Δ</i>	1.2 [0.6-2.0] x 10 ⁻⁴ (7948)	1.4 [0.9-2.1] x 10 ⁻⁵ (6533)	2.9 [1.1-3.7] x 10 ⁻⁵ (405)
<i>rnh201Δ</i>	2.1 [1.7-3.3] x 10 ⁻⁸ (2)	5.5 [4.2-7.4] x 10 ⁻⁹ (3)	1.3 [0.8-1.9] x 10 ⁻⁷ (2)
<i>CDC9-OE rnh201Δ</i>	9.6 [7.2-20.0] x 10 ⁻⁸ (7)	2.6 [1.9-3.2] x 10 ⁻⁸ (13)	6.0 [3.1-10.0] x 10 ⁻⁷ (8)
<i>exo1Δ rnh201Δ</i>	2.0 [1.3-3.3] x 10 ⁻⁷ (14)	1.7 [1.2-3.1] x 10 ⁻⁸ (8)	8.0 [6.7-10.0] x 10 ⁻⁷ (11)
<i>CDC9-OE exo1Δ rnh201Δ</i>	1.0 [0.5-2.0] x 10 ⁻⁵ (716)	1.2 [0.7-1.8] x 10 ⁻⁶ (561)	4.7 [1.8-6.6] x 10 ⁻⁶ (66)
<i>ELG1-OE</i>	5.8 [4.2-8.2] x 10 ⁻⁷ (40)	8.5 [5.4-16.5] x 10 ⁻⁹ (4)	4.4 [3.4-6.0] x 10 ⁻⁷ (6)
<i>ELG1-OE exo1Δ</i>	6.5 [4.9-8.5] x 10 ⁻⁷ (45)	4.7 [3.2-9.5] x 10 ⁻⁸ (23)	1.5 [1.0-2.0] x 10 ⁻⁶ (21)
<i>CDC9-OE ELG1-OE</i>	5.6 [2.8-11.9] x 10 ⁻⁷ (38)	2.3 [1.4-3.2] x 10 ⁻⁸ (11)	5.6 [3.1-9.8] x 10 ⁻⁷ (8)
<i>CDC9-OE exo1Δ ELG1-OE</i>	5.0 [2.8-7.3] x 10 ⁻⁵ (3387)	5.8 [3.5-9.1] x 10 ⁻⁶ (2809)	2.1 [1.5-3.6] x 10 ⁻⁵ (294)
<i>elg1Δ</i>	1.0 [0.7-1.9] x 10 ⁻⁷ (7)	4.8 [3.4-10.2] x 10 ⁻⁹ (2)	1.8 [1.5-2.3] x 10 ⁻⁷ (3)
<i>CDC9-OE elg1Δ</i>	2.3 [1.5-3.2] x 10 ⁻⁷ (16)	8.6 [5.8-11.1] x 10 ⁻⁹ (4)	3.4 [1.7-8.6] x 10 ⁻⁷ (6)
<i>exo1Δ elg1Δ</i>	1.5 [0.7-2.2] x 10 ⁻⁷ (10)	1.7 [1.4-2.6] x 10 ⁻⁸ (8)	7.8 [6.0-12.3] x 10 ⁻⁷ (11)
<i>CDC9-OE exo1Δ elg1Δ</i>	7.0 [4.2-11.7] x 10 ⁻⁷ (48)	7.4 [4.5-11.1] x 10 ⁻⁷ (355)	3.2 [1.9-4.4] x 10 ⁻⁶ (44)

Table S2. Increased Cdc9 ligase activity interferes with Exo1-dependent and Exo1-independent MMR. Related to Figure 2 and 3.

* Median rates *lys2-10A* (Lys⁺) and *hom3-10* (Thr⁺) frameshift reversion assays and inactivation of the *CAN1* gene (Can^R) with 95% confidence interval in square brackets and fold increase relative to the wild-type in parentheses.

	WT*	<i>CDC9-OE</i>	<i>exo1-F447A-F448A-Δ571-702</i>	<i>CDC9-OE exo1-F447A-F448A-Δ571-702</i>	<i>CDC9-OE msh2Δ</i>	<i>msh2Δ</i> **
Can^R clones sequenced	92	119	101	92	97	164
Mutations overall	92 (100.0)	119 (100.0)	101 (100.0)	92 (100.0)	98 (100.0)	169 (100.0)
Base substitutions	69 (75.0)	87 (73.1)	77 (76.2)	25 (27.2)	20 (20.4)	62 (37.0)
A-T → G-C	6 (6.5)	7 (5.9)	5 (5.0)	5 (5.4)	5 (5.1)	7 (4.1)
G-C → A-T	18 (19.6)	31 (26.1)	28 (27.7)	7 (7.6)	11 (11.2)	30 (17.8)
G-C → T-A	29 (31.5)	32 (26.9)	22 (21.8)	11 (12.0)	3 (3.1)	18 (10.7)
A-T → C-G	3 (3.3)	3 (2.5)	5 (5.0)	1 (1.1)	0 (0.0)	4 (2.4)
A-T → T-A	7 (7.6)	4 (3.4)	6 (5.9)	0 (0.0)	0 (0.0)	1 (0.6)
C-G → G-C	6 (6.5)	10 (8.4)	11 (10.9)	1 (1.1)	1 (1.0)	2 (1.2)
Transitions	24 (26.1)	38 (31.9)	33 (32.7)	12 (13.0)	16 (16.3)	37 (21.9)
Transversions	45 (48.9)	49 (41.2)	44 (43.6)	13 (14.1)	4 (4.1)	25 (14.8)
One-base-pair frameshifts	15 (16.3)	11 (9.2)	15 (14.9)	58 (63.0)	78 (79.6)	106 (63.0)
ΔA/T	5 (5.4)	2 (1.7)	7 (6.9)	34 (37.0)	56 (57.1)	75 (44.4)
ΔG/C	3 (3.3)	6 (5.0)	5 (5.0)	3 (3.3)	18 (18.4)	15 (8.9)
+A/T	6 (6.5)	3 (2.5)	2 (2.0)	21 (22.8)	4 (4.1)	13 (7.7)
+G/C	1 (1.1)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)	3 (1.8)
Complex mutations[†]	8 (8.7)	21 (17.6)	9 (8.9)	9 (9.8)	0 (0.0)	1 (1.0)

Table S3. *CAN1* mutation spectra in *CDC9-OE* strains and *exo1*-mutants. Related to Figure 2.

Mutation spectra analysis based on DNA sequencing of the *CAN1* gene in independent Can^R mutants, shown as the number of clones containing the indicated mutations, and in parenthesis as the percentage relative to the total. **CAN1* mutation spectrum of WT strain was taken from [S7]. ** *CAN1* mutation spectrum of *msh2Δ* strain was taken from [S8].

[†] includes multiple mutations within ten nucleotides, insertions or deletions of more than one nucleotide and duplication events.

type	occurrence	length deletion/ insertion	<i>CAN1-ORF</i> (nucleotides)	length flanking sequence
deletions				
8/119 (7%)				
	1/119	16 bp	76-91	5 bp
	2/119	27 bp	284-310	8 bp
	1/119	49 bp	762-810	11/12 bp [‡]
	1/119	15 bp	1134-1148	6 bp
	1/119	63 bp	1286-1348	8 bp
	1/119	16 bp	1324-1339	4 bp
	1/119	39 bp	1625-1663	6 bp
insertions				
9/119 (8%)				
	1/119	32 bp	225-256	6 bp
	1/119	18 bp	290-307	4 bp
	1/119	33 bp	399-431	4 bp
	1/119	128 bp	688-815	none
	1/119*	49 bp	762-810	11/12 bp [‡]
	1/119	72 bp	1265-1336	7 bp
	1/119	50 bp	1384-1433	5 bp
	1/119	38 bp	1580-1617	6 bp
	1/119	32 bp	1667-1698	5 bp

Table S4. Complex deletions and insertions found in the *CDC9-OE* strain (*CAN1* mutation spectrum). Related to Figure 2.

* mutation reported in the *rad27Δ CAN1* mutation spectrum [S9]. ‡ the sequence of the upstream flanking repeat is GGTGCTGGGGT (11 nt) and the sequence of the downstream flanking repeat is GGTGCCTGGGGT (12 nt).

Relevant genotype	Mutation Rate (fold increase) [†]		
	Lys ⁺	Thr ⁺	Can ^R
wild-type	1.5 [0.8-2.2] x 10 ⁻⁸ (1)	2.1 [1.4-3.2] x 10 ⁻⁹ (1)	7.2 [5.7-9.0] x 10 ⁻⁸ (1)
<i>G2/M-MSH6 msh3Δ</i> [#]	2.9 [1.7-4.7] x 10 ⁻⁵ (1983)	4.3 [3.3-5.5] x 10 ⁻⁶ (2069)	2.9 [2.1-4.3] x 10 ⁻⁶ (40)
<i>G2/M-CDC9</i>	8.0 [3.9-13.1] x 10 ⁻⁹ (5)	7.2 [4.8-10.0] x 10 ⁻⁹ (3)	4.0 [3.2-6.0] x 10 ⁻⁷ (6)
<i>G2/M-MSH6 msh3Δ G2/M-CDC9</i>	2.7 [1.7-3.9] x 10 ⁻⁵ (1813)	2.8 [1.5-4.1] x 10 ⁻⁶ (1330)	3.5 [2.2-4.8] x 10 ⁻⁶ (49)
<i>G2/M-PMS1</i>	6.1 [5.1-9.2] x 10 ⁻⁶ (418)	1.8 [1.3-2.4] x 10 ⁻⁷ (87)	5.9 [2.3-7.5] x 10 ⁻⁷ (8)
<i>G2/M-PMS1 G2/M-CDC9</i>	1.1 [0.8-1.5] x 10 ⁻⁶ (76)	4.2 [1.7-5.6] x 10 ⁻⁸ (20)	5.7 [4.3-10.1] x 10 ⁻⁷ (8)
<i>G2/M-PMS1 cdc9-FFAA</i>	2.8 [1.5-4.1] x 10 ⁻⁶ (194)	3.8 [2.7-6.5] x 10 ⁻⁸ (18)	2.1 [1.4-3.1] x 10 ⁻⁷ (3)
<i>G2/M-PMS1 exo1Δ</i>	4.6 [3.3-5.8] x 10 ⁻⁵ (3118)	2.1 [1.4-3.1] x 10 ⁻⁶ (991)	2.7 [1.9-3.2] x 10 ⁻⁶ (38)
<i>G2/M-PMS1 lys2-10A_{LATE}</i>	1.5 [1.4-1.9] x 10 ⁻⁶ (105)	1.2 [1.0-1.4] x 10 ⁻⁷ (59)	2.3 [1.8-3.4] x 10 ⁻⁷ (3)
<i>G2/M-PMS1 exo1Δ G2/M-CDC9</i>	2.3 [1.1-3.8] x 10 ⁻⁶ (157)	6.1 [4.4-8.0] x 10 ⁻⁸ (29)	1.4 [1.0-2.0] x 10 ⁻⁶ (20)
<i>cdc9-FFAA</i>	1.2 [1.0-1.7] x 10 ⁻⁸ (1)	3.4 [1.6-5.3] x 10 ⁻⁹ (2)	8.5 [7.3-17.3] x 10 ⁻⁸ (1)
<i>G2/M-PMS1 exo1Δ cdc9-FFAA</i>	7.8 [4.9-11.9] x 10 ⁻⁶ (536)	1.6 [0.9-2.4] x 10 ⁻⁷ (78)	1.1 [0.5-1.4] x 10 ⁻⁶ (15)
<i>G2/M-PMS1 exo1Δ elg1Δ</i>	1.2 [0.9-1.4] x 10 ⁻⁵ (794)	5.2 [3.4-9.4] x 10 ⁻⁷ (249)	1.8 [1.3-2.8] x 10 ⁻⁶ (26)

Table S5. MMR defect caused by the *G2/M-PMS1* allele is largely suppressed by delaying *Cdc9* expression or reducing *Cdc9* ligase activity. Related to Figure 4.

*Median rates of inactivation of the *CAN1* gene (Can^R) and *lys2-10A* (Lys⁺) and *hom3-10* (Thr⁺) frameshift reversion assays with 95% confidence interval in square brackets and fold increase relative to the wild-type in parentheses. # Mutation rates were taken from [S10].

Supplemental References

- S1. Johnson, C., Gali, V.K., Takahashi, T.S., and Kubota, T. (2016). PCNA Retention on DNA into G2/M Phase Causes Genome Instability in Cells Lacking Elg1. *Cell Rep* *16*, 684-695.
- S2. Kubota, T., Nishimura, K., Kanemaki, M.T., and Donaldson, A.D. (2013). The Elg1 replication factor C-like complex functions in PCNA unloading during DNA replication. *Mol Cell* *50*, 273-280.
- S3. Kubota, T., Katou, Y., Nakato, R., Shirahige, K., and Donaldson, A.D. (2015). Replication-Coupled PCNA Unloading by the Elg1 Complex Occurs Genome-wide and Requires Okazaki Fragment Ligation. *Cell Rep* *12*, 774-787.
- S4. Elledge, S.J., and Davis, R.W. (1990). Two genes differentially regulated in the cell cycle and by DNA-damaging agents encode alternative regulatory subunits of ribonucleotide reductase. *Genes Dev* *4*, 740-751.
- S5. Kumar, D., Viberg, J., Nilsson, A.K., and Chabes, A. (2010). Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint. *Nucleic Acids Res* *38*, 3975-3983.
- S6. Williams, L.N., Marjavaara, L., Knowels, G.M., Schultz, E.M., Fox, E.J., Chabes, A., and Herr, A.J. (2015). dNTP pool levels modulate mutator phenotypes of error-prone DNA polymerase epsilon variants. *Proc Natl Acad Sci U S A* *112*, E2457-2466.
- S7. Schmidt, T.T., Reyes, G., Gries, K., Ceylan, C.U., Sharma, S., Meurer, M., Knop, M., Chabes, A., and Hombauer, H. (2017). Alterations in cellular metabolism triggered by URA7 or GLN3 inactivation cause imbalanced dNTP pools and increased mutagenesis. *Proc Natl Acad Sci U S A* *114*, E4442-E4451.
- S8. Buckland, R.J., Watt, D.L., Chittoor, B., Nilsson, A.K., Kunkel, T.A., and Chabes, A. (2014). Increased and imbalanced dNTP pools symmetrically promote both leading and lagging strand replication infidelity. *PLoS genetics* *10*, e1004846.
- S9. Tishkoff, D.X., Filosi, N., Gaida, G.M., and Kolodner, R.D. (1997). A novel mutation avoidance mechanism dependent on *S. cerevisiae* RAD27 is distinct from DNA mismatch repair. *Cell* *88*, 253-263.
- S10. Hombauer, H., Srivatsan, A., Putnam, C.D., and Kolodner, R.D. (2011). Mismatch repair, but not heteroduplex rejection, is temporally coupled to DNA replication. *Science* *334*, 1713-1716.